Advertisement

Nitro Oxide And Ovarian Cancer

  • Robin Farias-Eisner
  • Gautam Chaudhuri
Conference paper

Abstract

The precise mechanisms by which the host defense to malignant tumors is mediated in vivo is not known. It is now believed that cancer cells themselves may trigger an immune response and this may limit the progression of the tumor. It is also possible to induce non specific resistance to cancer cells therapeutically. Intraperitoneal (i.p.) inoculation of Cornebacterium parvum, which increases nonspecific resistance to murine ovarian teratocarcinoma (MOT) cells can cure mice bearing these tumor cells [1]. Similarly, i.p. administration of Cornebacterium parvum to women [2] was at least partially effective in the treatment of minimal residual ovarian cancer in women. However, the mechanism by which this occurs is not known. Similarly, bacillus Calmette-Guerin (BCG) also appears to be an immununostimulant. When cultured in vitro, peritoneal macrophages obtained from mice previously inoculated with BCG release NO, which is cytostatic or cytolytic for tumor cells [3],[4]. This in vitro cytostatic and/or cytolytic activity is also observed after activation of the macrophages by cytokines [5],[6]. Interferon γ (INFγ) is important for the priming of macrophages, and tumor necrosis factor α (TNFα) or some other cytokine or bacterial lipopolysaccharide (LPS) is necessary for full induction of activated macrophage cytotoxicity [7],[8]. However, the role of NO in mediating tumoricidal activity in vivo and the mechanism by which this occurs is not exactly known. We therefore evaluated the role of NO in mediating both tumoricidal activity in vivo and the mechanism by which this occurs.

Keywords

Ovarian Cancer Host Resistance Ovarian Cancer Cell Line Human Ovarian Cancer OVCAR Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Knapp RC, Berkowitz RS (1977) Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer model. Am J Obstet Gynecol 128: 782–786PubMedGoogle Scholar
  2. 2.
    Bast RC Jr, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC (1983) Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res 43: 1395–1401PubMedGoogle Scholar
  3. 3.
    Hibbs JB Jr, Taintor RR, Chapman HA Jr, Weinberg JB (1977) Macrophage tumor killing: influence of the local environment. Science 197: 279–282PubMedCrossRefGoogle Scholar
  4. 4.
    Cleveland RP, Meltzer MS, Zbar B (1974) Tumor cytotoxicity in vitro by macrophages from mice infected with mycobacterium bovis strain BCG. J Natl Cancer Inst 52: 1887–1895PubMedGoogle Scholar
  5. 5.
    Pace JL, Russell SW, Torres BA, Johnson HM, Gray PW (1983) Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol 130:2011–2013PubMedGoogle Scholar
  6. 6.
    Lorsbach RB, Murphy WJ, Lowenstein CJ, Snyder SH, Russell SW (1993) Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing Molecular basis for the synergy between interferon-gamma and lipopolysaccharide J Biol Chem 268: 1908–1913PubMedGoogle Scholar
  7. 7.
    Drapier JC, Wietzerbin J, Hibbs JB Jr (1988) Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 18: 1587–1592PubMedCrossRefGoogle Scholar
  8. 8.
    Ding AH, Nathan CF, Stuehr DJ (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407–2412PubMedGoogle Scholar
  9. 9.
    Farias-Eisner R; Sherman MP; Aeberhard E; Chaudhuri G (1994) Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci 91: 9407–9411PubMedCrossRefGoogle Scholar
  10. 10.
    Farias-Eisner R, Chaudhuri G, Aeberhard E, Fukuto JM (1996) The chemistry and tumoricidal activity of nitric oxide/hydrogen peroxide and the implications to cell resistance/susceptibility. J Biol Chem 271: 6144–6151PubMedCrossRefGoogle Scholar
  11. 11.
    Bast RC Jr, Knapp RC, Donahue VC, Thurston JG, Mitchell AK, Feeney M, Schlossman SF (1980) Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. J Natl Cancer Inst 64: 365–372PubMedGoogle Scholar
  12. 12.
    Feldman GB, Knapp RC, Order SE, Hellman S (1972) The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 32: 1663–1666PubMedGoogle Scholar
  13. 13.
    FitzGerald DJ, Bjorn MJ, Ferris RJ, Winkelhake JL, Frankel AE, Hamilton TC, Ozols RF, Willingham MC, Pastan I (1987) Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer. Cancer Res 47: 1407–1410PubMedGoogle Scholar
  14. 14.
    Morales A, Ottenhof P, Emerson L (1981) Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin. J Urol 125: 649–651PubMedGoogle Scholar
  15. 15.
    van der Meijden AP, Steerenberg PA, van Hoogstraaten IM, Kerckhaert JA, Schreinemachers LM, Harthoorn-Lasthuizen EJ, Hagenaars AM, de Jong WH, Debruijne FM, Ruitenberg EJ (1989) Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guerin. Cancer Immunol Immunother 28: 287–295PubMedCrossRefGoogle Scholar
  16. 16.
    Alberts DS, Mason-Liddil N, O’Toole RV, Abbott TM, Kronmal R, Hilgers RD, Surwit EA, Eyre HJ, Baker LH (1989) Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: a Southwest Oncology Group Study. Gynecol Oncol 32: 16–21PubMedCrossRefGoogle Scholar
  17. 17.
    Likhite VV, Halpern BN (1974) Lasting rejection of mammary adenocarcinoma cell tumors in DBA-2 mice with intratumor injection of killed Corynebacterium parvum Cancer Res 34: 341–344PubMedGoogle Scholar
  18. 18.
    Bast RC Jr, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC (1983) Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res 43: 1395–1401PubMedGoogle Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Robin Farias-Eisner
  • Gautam Chaudhuri
    • 1
  1. 1.Department of Obstetrics and Gynecology and Melocular and Medical PharmacologyUCLA School of MedicineLos AngelesUSA

Personalised recommendations